How serialization helps detect illegitimate drugs

Serialization assigns an individual identity to each covered prescription-drug package. Under the Drug Supply Chain Security Act, the product identifier includes the National Drug Code, serial number, lot number and expiration date in human- and machine-readable form. The unique serial number makes it possible to distinguish one package from another that otherwise carries the same product and lot information.

Why a unique package identity matters

A lot number identifies a batch; serialization adds a package-level identity. If a package is reported stolen, recalled, duplicated or otherwise suspect, trading partners can compare its identifier and associated tracing records with the expected product information. A copied code or mismatch can trigger investigation. The identifier makes checks more specific than relying only on a product name or lot number.

Tracing follows ownership changes

The DSCSA established requirements for product tracing as covered prescription drugs move through the U.S. supply chain. Manufacturers, repackagers, wholesale distributors and dispensers must meet the requirements that apply to their roles. Enhanced interoperable electronic tracing helps authorized trading partners exchange and reconcile information about a product as ownership changes.

Verification supports suspect-product investigation

Verification checks use the product identifier to confirm that a product corresponds to a legitimate identifier or to investigate a suspect package. A dispenser that identifies a suspect product follows the applicable quarantine, investigation, notification and recordkeeping procedures. The serial number is a tool for tracing and verification, not an independent guarantee: an illegitimate actor may copy a legitimate identifier, so the package, records, trading partner and investigation all matter.

What a pharmacy technician should understand

Technicians may receive, scan, stock or otherwise handle products under pharmacy procedures. They should recognize why a mismatch, unreadable identifier, unexplained packaging issue or system alert cannot simply be ignored. Follow the pharmacist or compliance lead's process: hold or segregate the product when directed, preserve relevant information, and escalate. Do not independently return questionable product to stock or declare it genuine based only on a successful barcode scan.

Serialization is one layer of supply-chain security

• Unique identifiers help distinguish packages and support tracing.
• Verification can expose mismatches and support suspect-product investigations.
• Authorized trading partner status and transaction records help establish a legitimate chain of custody.
• Physical packaging and shipment anomalies may still matter even when a code scans.
• A scan does not replace required records, procedures, quarantine or reporting steps.

Exam traps

• Confusing an NDC or lot number with the unique serial number.
• Assuming serialization means every scan conclusively proves authenticity.
• Thinking DSCSA applies only to manufacturers; dispensers are also covered trading partners.
• Treating a suspicious package as routine inventory instead of escalating under procedure.
• Assuming a technician independently makes the final regulatory determination when pharmacy policy assigns that role to the pharmacist or compliance staff.

Key takeaway

Serialization gives a covered package a unique identity. Combined with tracing, verification and authorized supply-chain controls, that identity helps trading partners detect and investigate suspect product; it is not a stand-alone authenticity certificate.

Serialization supports verification but does not prove authenticity by itself

A DSCSA product identifier includes standardized information at the package level, including the product’s NDC, a unique serial number, lot number, and expiration date in the required format. The serialized identifier supports tracing and verification, but a readable code alone does not establish that a package is genuine. The pharmacy must receive product from authorized trading partners, maintain required transaction information and statements, and follow verification and suspect-product procedures. Compare the product identifier with the physical product and transaction records when a discrepancy or suspect signal appears.

Potential warning signs include a missing or unreadable identifier where one is required, an identifier that fails verification, mismatched lot or expiration data, an unexpected source, tampering, or a product that does not match its transaction documents. These are triggers to stop distribution and follow the pharmacy’s quarantine and escalation procedure, not proof that a specific person committed wrongdoing. Do not delete the alert or relabel the package to make it pass. Contact the responsible pharmacist/compliance lead and follow FDA reporting requirements where applicable.

Practical checks, exceptions, and exam application

The identifier must be preserved through receiving and dispensing workflows. Do not obscure it with a pharmacy label where the source packaging must remain available for verification, and do not assume that a scan will capture every required data element. Where policy requires, compare the serialized package with the transaction information and investigate mismatches. A product from a legitimate wholesaler can still arrive damaged or have an identifier that needs resolution. Handle exceptions through the authorized verification workflow.

Suspect-product procedures should include isolation, documentation, notification, and any required FDA or trading-partner communication. Quarantine means the product is prevented from being dispensed while the issue is assessed; it does not mean destroying it immediately. Preserve packaging and transaction records. If a package is illegitimate or a trading partner is unauthorized, the responsible compliance person determines required reporting and notification.

DSCSA applies to covered prescription drugs and has defined exemptions and enforcement policies. Do not generalize a temporary stabilization policy or a narrow exemption into a permanent rule for all dispensers. For current compliance decisions, use FDA’s current DSCSA pages and counsel/compliance direction; for exam study, focus on the identifier’s elements and the suspect-product response.

Final workflow check

A scan failure can have benign causes, such as damaged print, but staff must not resolve it by assuming the product is legitimate. Use the documented alternate verification method and retain the outcome. If a product identifier is duplicated, already decommissioned, or inconsistent with the package, hold the product and escalate. Only authorized personnel should communicate with the trading partner or FDA on behalf of the pharmacy, and all required timelines should be followed.